Journal Watch · British Journal of Pharmacology · 2026

Identification of drug repurposing candidates for the treatment of polycystic kidney disease.

Engagement of several targets was achieved at clinically relevant concentrations.<h4>Conclusions and implications</h4>We have identified novel targets of three repurposing candidates that contribute to the cyst growth reducing effects in preclinical ADPKD models and identify salicylic acid, the metabolite of aspirin, as the repurposing candidate with the most promising mechanisms of action.

Meyer A, Sotiropoulou P, Bouker K et al.British Journal of Pharmacology3 min readPharma relevance 50/100

DOI: 10.1111/bph.70493PMID: 42184822Study type: research study

TL;DR

Engagement of several targets was achieved at clinically relevant concentrations.<h4>Conclusions and implications</h4>We have identified novel targets of three repurposing candidates that contribute to the cyst growth reducing effects in preclinical ADPKD models and identify salicylic acid, the metabolite of aspirin, as the repurposing candidate with the most promising mechanisms of action.

Key findings

  • Engagement of several targets was achieved at clinically relevant concentrations.<h4>Conclusions and implications</h4>We have identified novel targets of three repurposing candidates that contribute to the cyst growth reducing effects in preclinical ADPKD models and identify salicylic acid, the metabolite of aspirin, as the repurposing candidate with the most promising mechanisms of action.

What they did

As expected, salicylic acid displayed a polypharmacological profile but also engaged enzymes along the N-linked glycosylation pathway and inhibited PTK2 (FAK), an activator of the proliferative PI3K/Akt/mTOR pathway. Orthogonal assays and computational modelling confirmed these findings and located the binding site (499-504) of salicylic acid within PTK2's ATP-binding pocket.

Full abstract (original)

Background: <h4>Background and purpose</h4>Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments.<h4>Experimental approach</h4>We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and applied thermal proteome profiling to identify disease-relevant targets.<h4>Key results</h4>Our results uncovered shared effects between the three drugs, including a thermal shift in ADP/ATP translocases (SLC25A4/5/6) caused by reduced ATP production.

What they did: As expected, salicylic acid displayed a polypharmacological profile but also engaged enzymes along the N-linked glycosylation pathway and inhibited PTK2 (FAK), an activator of the proliferative PI3K/Akt/mTOR pathway. Orthogonal assays and computational modelling confirmed these findings and located the binding site (499-504) of salicylic acid within PTK2's ATP-binding pocket.

Results & conclusions: Engagement of several targets was achieved at clinically relevant concentrations.<h4>Conclusions and implications</h4>We have identified novel targets of three repurposing candidates that contribute to the cyst growth reducing effects in preclinical ADPKD models and identify salicylic acid, the metabolite of aspirin, as the repurposing candidate with the most promising mechanisms of action.

Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70493 · PubMed 42184822.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this British Journal of Pharmacology study find?

Engagement of several targets was achieved at clinically relevant concentrations.<h4>Conclusions and implications</h4>We have identified novel targets of three repurposing candidates that contribute to the cyst growth reducing effects in preclinical ADPKD models and identify salicylic acid, the metabolite of aspirin, as the repurposing candidate with the most promising mechanisms of action.

What type of study is this?

It is a research study, published in British Journal of Pharmacology in 2026. As expected, salicylic acid displayed a polypharmacological profile but also engaged enzymes along the N-linked glycosylation pathway and inhibited PTK2 (FAK), an activator of the proliferative PI3K/Akt/mTOR pathway.

Where can I read the original paper?

The original is at the publisher via DOI 10.1111/bph.70493. PubMed ID: 42184822. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Meyer A, Sotiropoulou P, Bouker K et al.. Identification of drug repurposing candidates for the treatment of polycystic kidney disease.. British Journal of Pharmacology (2026). DOI: 10.1111/bph.70493.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/identification-of-drug-repurposing-candidates-for-the-treatment-of-polyc-h70493/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides